Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.

Rasihashemi, Seyed Z; Rezazadeh Gavgani, Erfan; Majidazar, Reza; Seraji, Parya; Oladghaffari, Mobina; Kazemi, Tohid; Lotfinejad, Parisa

Rasihashemi, Seyed Z; Rezazadeh Gavgani, Erfan; Majidazar, Reza; Seraji, Parya; Oladghaffari, Mobina; Kazemi, Tohid; Lotfinejad, Parisa.

Afiliação

Rasihashemi SZ; Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran.
Rezazadeh Gavgani E; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Majidazar R; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Seraji P; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Oladghaffari M; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Kazemi T; Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran.
Lotfinejad P; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

J Cell Physiol ; 237(3): 1648-1660, 2022 03.

Article em En | MEDLINE | ID: mdl-34825383

Assuntos

Exossomos; Neoplasias; Antígeno B7-H1/metabolismo; Exossomos/metabolismo; Humanos; Tolerância Imunológica; Fatores Imunológicos/farmacologia; Imunoterapia; Neoplasias/patologia

Palavras-chave

PD-L1; cancer progression; exosomal PD-L1; immunotherapy; tumor-derived exosomes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Exossomos / Neoplasias Tipo de estudo: Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google